Anton Rx Report

The FDA recently approved a new ORAL therapy, Jaypirca (pirtobrutinib) from Eli Lilly and Company, indicated for mantle cell lymphoma (MCL) after at least two

The day has finally arrived. The day when a biosimilar to Humira finally hits the market. A total of 40 biosimilars have been approved since

Acronyms….. they seem to be everywhere….. especially in healthcare.  One acronym that has surfaced in the specialty pharmacy world is MIP.  Scratching your head on what that

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely

The FDA recently approved a biologics license application (BLA) for a new infused therapy, Briumvi from TG Therapeutics, Inc., indicated for the treatment of relapsing

Earlier this month the FDA approved a new infused therapy, Leqembi (lecanemab-irmb) from Eisai R&D Management Co., Ltd., indicated for the treatment of Alzheimer’s disease. Therapy

The FDA recently approved a novel gene therapy, Adstiladrin (nadofaragene firadenovec-vncg) from Ferring Pharmaceuticals A/S, indicated for the treatment of adult patients with high-risk Bacillus

The FDA recently approved a new antiviral therapy regimen, Sunlenca (lenacapavir) from Gilead Sciences, indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults

So, can you easily explain the differences between a chemically synthesized drug and a biologic?  You might be surprised how difficult that has become. The

We know that there are a limited number of specialty pharmacies in the US. A small number of customers makes it hard for any new product